Greenyn Biotechnology Co., Ltd. AI Stock Analysis
Greenyn Biotechnology Co., Ltd. (6846) AI Stock Analysis
Greenyn Biotechnology Co., Ltd.
(TPEx:6846)
The overall score is constrained by significant financial and technical headwinds. The primary risk is the company's deteriorating financial health, marked by a surge in leverage and deeply negative free cash flow, which raises concerns about the sustainability of its operations and dividend. This is compounded by a very weak technical posture, with the stock in a clear downtrend and showing strong bearish momentum. A low P/E ratio and high dividend yield provide a partial offset, but these are overshadowed by the fundamental and market-driven risks.
Greenyn Biotechnology Co., Ltd. (6846) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.33B
- Dividend Yield
- 8.05%
- Average Volume (3M)
- 12.90K
- Price to Earnings (P/E)
- 10.2
- Beta (1Y)
- 0.36
- Revenue Growth
- -3.09%
- EPS Growth
- -27.22%
- Country
- TW
- Employees
- 143
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Greenyn Biotechnology Co., Ltd. Business Overview & Revenue Model
Company Description
Greenyn Biotechnology Co., Ltd is an enterprise specializing in dietary supplements, dedicated to the development, production, and worldwide distribution of health-enhancing products. Their product portfolio includes a range of proprietary active ing...
Greenyn Biotechnology Co., Ltd. Financial Statement Overview
Summary
Revenue growth is a positive, but financial health has deteriorated sharply. Profit margins are compressing, the balance sheet has become highly leveraged with debt-to-equity spiking to 0.94, and free cash flow is deeply negative. The overall financial picture is strained, with cash generation unable to support investments.
Income Statement
72PositiveBalance Sheet
45NeutralCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 867.63M | 915.32M | 873.24M | 800.51M | 705.31M | 693.77M |
| Gross Profit | 405.39M | 440.04M | 415.23M | 392.46M | 370.93M | 358.02M |
| EBITDA | 204.77M | 224.08M | 215.81M | 192.40M | 210.40M | 193.67M |
| Net Income | 127.24M | 145.52M | 146.00M | 130.66M | 146.74M | 132.78M |
Balance Sheet | ||||||
| Total Assets | 2.47B | 2.11B | 1.11B | 1.16B | 834.81M | 844.86M |
| Cash, Cash Equivalents and Short-Term Investments | 1.18B | 1.15B | 552.53M | 533.66M | 370.45M | 436.30M |
| Total Debt | 1.22B | 915.56M | 65.71M | 196.13M | 85.73M | 70.20M |
| Total Liabilities | 1.55B | 1.13B | 257.32M | 364.48M | 272.80M | 231.09M |
| Stockholders Equity | 917.96M | 978.56M | 851.35M | 796.91M | 562.01M | 613.76M |
Cash Flow | ||||||
| Free Cash Flow | -333.10M | -236.18M | 209.89M | 37.73M | 212.59M | 64.05M |
| Operating Cash Flow | 130.03M | 158.90M | 219.66M | 127.10M | 229.73M | 81.79M |
| Investing Cash Flow | -674.50M | -753.95M | 33.77M | -155.75M | -16.41M | -18.82M |
| Financing Cash Flow | 499.45M | 836.37M | -234.57M | 191.86M | -199.15M | -90.98M |
Greenyn Biotechnology Co., Ltd. Peers Comparison
Overall Rating
TW:417357Neutral- TW:684650Neutral
TW:419043Neutral
TW:643138Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4173 | 57Neutral | TWD 1.33B | 22.44 | ― | 5.81% | 10.77% | -35.84% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6846 | 50Neutral | TWD 1.33B | 10.22 | ― | 8.05% | -3.09% | -27.22% |
| TW:4190 | 43Neutral | TWD 1.29B | -13.57 | ― | 2.30% | -1.05% | 34.07% |
| TW:6431 | 38Underperform | TWD 1.45B | -7.50 | ― | ― | -14.57% | 13.16% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6846 | Greenyn Biotechnology Co., Ltd. | 49.00 | -24.13 | -32.99% | |
| TW:4173 | Arich Enterprise Co., Ltd. | 17.90 | -2.84 | -13.70% | |
| TW:4190 | Jourdeness Group Ltd. | 21.75 | -9.03 | -29.35% | |
| TW:6431 | Kuangli Bio-Tech Holdings Co., Ltd. | 14.85 | -1.45 | -8.90% | |
| TW:6886 | Far East Bio-Tec. Co., Ltd. | 38.65 | -2.71 | -6.56% | |
| TW:6935 | Prince Pharmaceutical Co., Ltd. | 28.20 | -1.01 | -3.47% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026